Application note: A kinase inhibitor phenotypic screen using a multiplex T Cell activation assay
Posted: 22 June 2020 | IntelliCyt Corporation | No comments yet
Modulating the TCR signaling pathway using biologics, small molecules or genetic engineering is highly relevant to many therapeutic areas including cancer immunotherapy, adoptive cell therapy, vaccine development and autoimmune disease.
Kinase inhibitor drugs specifically targeting early signaling events during T cell activation are a new focus for the treatment of autoimmune diseases. The development of these drugs and therapies regulating TCR activity require assays that can rapidly profile T cell function and health.
This application note describes high throughput screening of a library of kinase inhibitors for T-cell activation inhibition using primary human PBMCs by simultaneous evaluation of activation markers, cell proliferation and cytokines in a single assay.
Related content from this organisation
- Whitepaper: Addressing the challenges in biologics discovery with advanced flow cytometry
- Article: Immuno-oncology: Pushing the frontier of discovery through advanced high throughput flow cytometry
- Application note: A kinase inhibitor phenotypic screen using a multiplex T Cell activation assay
- Training and development in flow cytometry and other core technologies
- Expert view: Opportunities in flow cytometry
Related topics
Assays, Biologics, Biotherapeutics, Kinases, Small molecule
Related organisations
IntelliCyt Corporation